Climb Bio reported third-quarter results and updates across its clinical-stage programs in kidney and immune-mediated diseases. The company highlighted early clinical data for CLYM116 and budoprutug, outlined upcoming trial milestones, and said its cash balance is expected to fund operations into the second half of 2028.
The update also included a new corporate presentation. The financial information provided here gives the company’s cash position and runway, but no revenue or expense figures.
Key details
- CLYM116 in IgA nephropathy: Climb Bio has begun dosing patients in NAVIGATE-2, a Phase 2 study testing the drug in IgA nephropathy. The trial compares an 800 mg loading dose followed by 400 mg every eight weeks or every 12 weeks. Enrollment is ongoing.
- Trial milestones: The company expects initial NAVIGATE-2 results in the first half of 2027. It plans to start a global Phase 3 trial in 2027, subject to regulatory feedback.
- Evidence supporting less-frequent dosing: Across two Phase 1 studies in healthy volunteers, a single dose of at least 480 mg kept free APRIL suppression above 90% through 12 weeks. After an 800 mg dose, Gd-IgA1 fell about 70% and total IgA about 60% at 12 weeks. Climb Bio said the results support a 12-week dosing interval.
- CLYM116 safety: The drug was generally well tolerated in those studies, with no dose-limiting toxicities, treatment-related serious adverse events or hypogammaglobulinemia. The two studies enrolled 46 and 42 participants.
- Budoprutug in membranous nephropathy: Initial results from the Phase 2 PrisMN study showed that the 200 mg dose depleted B cells, reduced anti-PLA2R antibodies and produced immunologic remission by Week 12. The patients in the reported cohorts had persistent proteinuria and elevated antibody levels at baseline. Enrollment is continuing.
- More pMN data ahead: PrisMN is testing escalating doses to assess safety and biological activity and to help select a dose for later-stage development. Initial observations from the 600 mg cohort indicated greater drug exposure; the company said higher doses may have the potential for greater activity. Additional results across cohorts, including longer-term follow-up, are expected in 2027.
- Budoprutug in lupus: Initial Phase 1b results in systemic lupus erythematosus showed dose-dependent B-cell depletion after single doses of 10–100 mg, along with reductions in SLEDAI-2K disease-activity scores. The company described the drug as generally well tolerated, with no serious adverse events.
- Upcoming ITP update: Climb Bio expects to present additional Phase 1b budoprutug data in immune thrombocytopenia at the American Society of Hematology meeting in December 2026.
- Cash and runway: Climb Bio had $227.6 million in cash, cash equivalents and marketable securities on September 30, 2026. It expects that balance to fund operations into the second half of 2028.
Plain-English implications
The CLYM116 data support testing a 12-week dosing schedule in patients, while NAVIGATE-2 is intended to help determine whether that regimen can advance to Phase 3. For budoprutug, the early pMN and lupus findings show biological activity, but the ongoing studies are still assessing dose and clinical potential. The stated cash runway extends into the period when the company expects several important 2027 data updates and a possible start to Phase 3 testing.